Comparison of psychotropic drug preferences and side effects in old and young patients with schizophrenia and schizoaffective disorder

Author:

UÇAR Zehra1ORCID,YILDIRIM Betül1,TATLI Safiye Zeynep1,ÖZEL KIZIL Erguvan Tuğba1

Affiliation:

1. Ankara University School of Medicine, Department of Psychiatry

Abstract

Purpose: The current study investigates the preferred psychotropic drug treatments and their tolerability in elderly patients (EP) with a diagnosis of schizophrenia or schizoaffective disorder compared to younger patients (YP). Materials and Methods: The study included 154 EP and 195 YP with schizophrenia/schizoaffective disorder admitted to the outpatient unit at a university hospital in the last decade. The medical records of the patients were reviewed. The types and doses of antipsychotic drugs used by each patient, use of other psychotropic drugs, ongoing complaints, drug-related side effects and compliance with treatment were also examined. Results: Second generation antipsychotic use was higher in YP (88% in YP, 80% in EP). Antipsychotic equivalent doses were found 266.63 mg in EP, 522.21 mg in YP, that also higher in the YP group. The use of clozapine (7% in EP, 37% in YP) and mood stabilizers (4.5% in EP, 18% in YP) were higher in YP. There was a higher rate of dose reduction of antipsychotic drugs in EP (21.5% in YP, 52% in EP). When the groups were compared in terms of the reasons of antipsychotic dose reduction, it was more frequent in EP due to side effects (21.4% in YP, 40% in EP), while the dose reduction due to remission was more common in YP (78.6% in YP, 60% in EP) . Conclusion: Lower doses of antipsychotics in EP suggests milder symptoms or lower tolerability. The higher clozapine and mood stabilizer use in YP can be explained by avoiding side effects like extrapyramidal, cardiovascular and metabolic side effects that are more frequent in EP.

Publisher

Cukurova Medical Journal

Subject

General Earth and Planetary Sciences,General Environmental Science

Reference27 articles.

1. 1. Erol A, Kılıçaslan EE. Symptom pattern and clinical course in schizophrenia. In schizophrenia and other psychotic disorders (Eds Danacı AE Böke Ö, Saka MC, Erol A, Kaymak SU):13-29. Ankara, Turkish Psychiatric Association, 2018.

2. 2. Lawrence RE, First MB. Psychopathology. In The american psychiatric association publishing textbook of schizophrenia second edition (Eds Lieberman JA, Stroup ST, Perkins DO, Dixon LB):35-52. Washington, 2020.

3. 3. Ng B, Martinez S, Koh S, Tohen M, Gangwisch JE. Epidemiology. In The american psychiatric association publishing textbook of schizophrenia second edition (Eds Lieberman JA, Stroup ST, Perkins DO, Dixon LB):3-11. Washington, 2020.

4. 4. Hjorthoj C, Sturup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry 2017; 4(4): 295-301.

5. 5. Solomon HV, Sinopoli M, DeLisi LE. Ageing with schizophrenia: an update. Current Opinion in Psychiatry 2021; 34(3): 266-74.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3